Alzheimer's disease-A panorama glimpse

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12631-12650

  Zhao, Li Na ^a   Lu, Lanyuan ^a   Chew, Lock Yue ^a   Mu, Yuguang ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Alzheimer's disease; Amyloid oligomer; Amyloid peptide; A polymorphism; A variants; Pyroglutamate modified amyloid beta peptides; Tau protein

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DONEPEZIL; GALANTAMINE; GLUTAMATE RECEPTOR; MEMANTINE; RIVASTIGMINE; TAU PROTEIN; CHOLINESTERASE INHIBITOR; ISOPROTEIN; NOOTROPIC AGENT; PYROGLUTAMIC ACID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; DNA DAMAGE; EXCITOTOXICITY; GENE MUTATION; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; REVIEW; X RAY CRYSTALLOGRAPHY; CHEMISTRY; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHOLINESTERASE INHIBITORS; HUMANS; NOOTROPIC AGENTS; PROTEIN ISOFORMS; PYRROLIDONECARBOXYLIC ACID; TAU PROTEINS;

EID: 84904439334     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712631     Document Type: Review

References (150)

1. Duthey, B. Background paper 6. 11: Alzheimer disease and other dementias. A Public Health Approach to Innovation; Update on 2004 Background Paper, 2013; pp. 1-74. Available online: http://www. who. int/medicines/areas/priority medicines/BP6 11Alzheimer. pdf (accessed on 8 June 2014).
2. Weuve, J.; Hebert, L. E.; Scherr, P. A.; Evans, D. A. Deaths in the United States among persons with Alzheimer's disease (2010-2050). Alzheimer's Dement.: J. Alzheimer's Assoc. 2014, 10, e40-e46.
3. Ritchie, K.; Kildea, D.; Robine, J. M. The relationship between age and the prevalence of senile dementia: A meta-analysis of recent data. Int. J. Epidemiol. 1992, 21, 763-769.
4. Bird, T. D. Alzheimer disease overview. In GeneReviewsTM [Internet]; Pagon, R. A., Bird, T. D., Dolan, C. R., et al., Eds.; University of Washington: Seattle, WA, USA, 1998.
5. Duara, R.; Alberola, R. F.; Barker, W. W.; Loewenstein, D. A.; Zatinsky, M.; Eisdorfer, C. E.; Weinberg, G. B. A comparison of familial and sporadic Alzheimer's disease. Neurobiology 1993, 43, 1377-1384.
6. Bird, T. D. Genetic aspects of Alzheimer disease. Genet. Med. 2008, 10, 231-239.
7. Gatz, M.; Reynolds, C. A.; Fratiglioni, L.; Johansson, B.; Mortimer, J. A.; Berg, S.; Fiske, A.; Pedersen, N. L. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 2006, 63, 168-174.
8. Minati, L.; Edginton, T.; Bruzzone, M. G.; Giaccone, G. Current concepts in Alzheimer's disease: A multidisciplinary review. Am. J. Aszheimers Dis. Other Dement. 2009, 24, 95-121.
9. Combarros, O.; Arcaya, A.; Guerra, M.; Infante, J.; Berciano, J. Candidate gene association studies in sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2002, 14, 41-54.
10. Mucke, L. Neuroscience: Alzheimer's disease. Nature 2009, 461, 895-897.
11. Anitha, S. Studies on DNA Topology and DNA-Amyloid Beta (Aβ) Peptides Interaction in Relevance to Alzheimer's Disease. Ph. D. Thesis, University of Mysore, Mysore, India, 2005.
12. Suberbielle, E.; Sanchez, P. E.; Kravitz, A. V.; Wang, X.; Ho, K.; Eilertson, K.; Devidze, N.; Kreitzer, A. C.; Mucke, L. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β. Nat. Neurosci. 2013, 16, 613-621.
13. Schellenberg, G. D.; Bird, T. D.; Wijsman, E. M.; Orr, H. T.; Anderson, L.; Nemens, E.; White, J. A.; Bonnycastle, L.; Weber, J. L.; Alonso, M. E. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992, 258, 668-671.
14. Cruts, M.; Hendriks, L.; Broeckhoven, C. V. The presenilin genes: A new gene family involved in Alzheimer disease pathology. Hum. Mol. Genet. 1996, 5, 1449-1465.
15. Schellenberg, G. D.; Pericak-Vance, M. A.; Wijsman, E. M.; Moore, D. K.; Gaskell, P. C.; Yamaoka, L. A.; Bebout, J. L.; Anderson, L.; Welsh, K. A.; Clark, C. M.; et al. Linkage analysis of familial Alzheimer disease, using chromosome 21 markers. Am. J. Hum. Genet. 1991, 48, 563-583.
16. Bird, T. D.; Levy-Lahad, E.; Poorkaj, P.; Sharma, V.; Nemens, E.; Lahad, A.; Lampe, T. H.; Schellenberg, G. D. Wide range in age of onset for chromosome 1-related familial Alzheimer's disease. Ann. Neurol. 1996, 40, 932-936.
17. George-Hyslop, P. H. S.; Tanzi, R. E.; Polinsky, R. J.; Haines, J. L.; Nee, L.; Watkins, P. C.; Myers, R. H.; Feldman, R. G.; Pollen, D.; Drachman, D. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987, 235, 885-890.
18. Saunders, A. M.; Strittmatter, W. J.; Schmechel, D.; George-Hyslop, P. H. S.; Pericak-Vance, M. A.; Joo, S. H.; Rosi, B. L.; Gusella, J. F.; Crapper-MacLachlan, D. R.; Alberts, M. J.; et al. Association of apolipoprotein E allele epsilon4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43, 1467-1472.
19. Naj, A. C.; Beecham, G. W.; Martin, E. R.; Gallins, P. J.; Powell, E. H.; Konidari, I.; Whitehead, P. L.; Cai, G.; Haroutunian, V.; Scott, W. K.; et al. Dementia revealed: Novel chromosome 6 locus for late-onset alzheimer disease provides genetic evidence for folate-pathway abnormalities. PLoS Genet. 2010, 6, e1001130.
20. Poduslo, S. E.; Yin, X. A new locus on chromosome 19 linked with late-onset Alzheimer's disease. Neuroreport 2001, 12, 3759-3761.
21. Wijsman, E. M.; Daw, E. W.; Yu, C.; Payami, H.; Steinbart, E. J.; Nochlin, D.; Conlon, E. M.; Bird, T. D.; Schellenberg, G. D. Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13. 2. Am. J. Hum. Genet. 2004, 75, 398-409.
22. Scott, W. K.; Grubber, J. M.; Conneally, P. M.; Small, G. W.; Hulette, C. M.; Rosenberg, C. K.; Saunders, A. M.; Roses, A. D.; Haines, J. L.; Pericak-Vance, M. A. Fine mapping of the chromosome 12 late-onset alzheimer disease locus: Potential genetic and phenotypic heterogeneity. Am. J. Hum. Genet. 2000, 66, 922-932.
23. Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere M. L.; Pahwa, J. S.; Moskvina, V.; Dowzell, k.; Williams, A.; et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes. Nat. Genet. 2009, 41, 1088-1093.
24. Heinzen, E. L.; Need, A. C.; Hayden, K. M.; Chiba-Falek, O.; Roses, A. D.; Strittmatter, W. J.; Burke, J. R.; Hulette, C. M.; Welsh-Bohmer, K. A.; Goldstein, D. B. Genome-wide scan of copy number variation in late-onset Alzheimer's disease. J. Alzheimers Dis. 2010, 19, 69-77.
25. Swaminathan, S.; Shen, L.; Kim, S.; Inlow, M.; West, J. D.; Faber, K. M.; Foroud, T.; Mayeux, R.; Saykin, A. J. Analysis of copy number variation in Alzheimer's disease: The NIALOAD/NCRAD family study. Curr. Alzheimer Res. 2012, 9, 801-814.
26. Arriagada, P. V.; Growdon, J. H.; Hedley-Whyte, E. T.; Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42, 631-639.
27. Chen, F.; David, D.; Ferrari, A.; Gotz, J. Posttranslational modifications of tau-Role in human tauopathies and modeling in transgenic animals. Curr. Drug Targets 2004, 13, 503-515.
28. Flaherty, D. B.; Soria, J. P.; Tomasiewicz, H. G.; Wood, J. G. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3b and cdk5 are key participants. J. Neurosci. Res. 2000, 62, 463-472.
29. Avila, J.; Lucas, J. J.; Pérez, M.; Herández, F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 2004. 84, 361-384.
30. Hoover, B. R.; Reed, M. N.; Su, J.; Penrod, R. D.; Kotilinek, L. A.; Grant, M. K.; Pitstick, R.; Carlson, G. A.; Lanier, L. M.; Yuan, L. L.; et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68, 1067-1081.
31. Crowther, R. A.; Wischik, C. M. Image reconstruction of the Alzheimer paired helical filament. EMBO J. 1985, 4, 3661-3665.
32. Friedhoff, P.; von Bergen, M.; Mandelkow, E. M.; Mandelkow, E. Structure of tau protein and assembly into paired helical filaments. BBA-Protein Proteom. 2000, 1502, 122-132.
33. Hoe, H. S.; Lee, K. J.; Carney, R. S.; Lee, J.; Markova, A.; Lee, J. Y.; Howell, B, W.; Hyman, B. T.; Pak, D. T.; Bu, G.; et al. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J. Neurosci. 2009, 29, 7459-7473.
34. Bellingham, S. A.; Ciccotosto, G. D.; Needham, B. E.; Fodero, L. R.; White, A. R.; Masters, C. L.; Cappai, R.; Camakaris, J. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J. Neurochem. 2004, 91, 423-428.
35. Priller, C.; Bauer, T.; Mitteregger, G.; Krebs, B.; Kretzschmar, H. A.; Herms, J. Synapse formation and function is modulated by the amyloid precursor protein. Neurobiol. Dis. 2006, 26, 7212-7221.
36. H'erard, A. S.; Besret, L.; Dubois, A.; Dauguet, J.; Delzescaux, T.; Hantraye, P.; Bonvento, G.; Moya, K. L. siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo. Neurobiol. Aging 2006, 27, 1740-1750.
37. Zheng, H.; Jiang, M.; Trumbauer, M. E.; Sirinathsinghji, D. J. S.; Hopkins, R.; Smith, D. W.; Heavens, R. P.; Dawson, G. R.; Boyce, S.; Conner, M. W.; et al. β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995, 81, 525-531.
38. Kirkitadze, M. D.; Bitan, G.; Teplow, D. B. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci. Res. 2002, 69, 567-577.
39. Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C. M.; Stefani, M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416, 507-511.
40. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; Rowan, M. J.; Selkoe, D. J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416, 535-539.
41. Resende, R.; Ferreiro, E.; Pereira, C.; de Oliveira, C. R. Neurotoxic effect of oligomeric and fibrillar species of amyloid β peptide 1-42: Involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 2008, 155, 725-737.
42. Haass, C.; Selkoe, D. J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8, 101-112.
43. Donald, J. M. M.; Savva, G. M.; Brayne, C.; Welzel, A. T.; Forster, G.; Shankar, G. M.; Selkoe, D. J.; Ince, P. G.; Walsh, D. M. The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia. Brain 2010, 133, 1328-1341.
44. Talafous, J.; Marcinowski, K. J.; Klopman, G.; Zagorski, M. G. Solution structure of residues 1-28 of the amyloid beta-peptide. Biochemistry 1994, 33, 7788-7796.
45. Sticht, H.; Bayer, P.; Willbold, D.; Dames, S.; Hilbich, C.; Beyreuther, K.; Frank, R. W.; Rosch, P. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 1995, 233, 293-298.
46. Coles, M.; Bicknell, W.; Watson, A. A.; Fairlie, D. P.; Craik, D. J. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 1998, 37, 11064-11077.
47. Watson, A. A.; Fairlie, D. P.; Craik, D. J. Solution structure of methionine-oxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching? Biochemistry 1998, 37, 12700-12706.
48. Poulsen, S. A.; Watson, A. A.; Craik, D. J. Solution structures in aqueous SDS micelles of two amyloid beta peptides of A β(1-28) mutated at the β-secretase cleavage site (K16E, K16F). J. Struct. Biol. 2000, 130, 142-152.
49. Zhang, S.; Iwata, K.; Lachenmann, M. J.; Peng, J. W.; Li, S.; Stimson, E. R.; Lu, Y.; Felix, A. M.; Maggio, J. E.; Lee, J. P. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J. Struct. Biol. 2000, 130, 130-141.
50. Crescenzi, O.; Tomaselli, S.; Guerrini, R.; Salvadori, S.; D'Ursi, A. M.; Temussi, P. A.; Picone, D. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur. J. Biochem. 2002, 269, 5642-5648.
51. Huang, J.; Yao, Y.; Lin, J.; Ye, Y. H.; Sun, W. Y.; Tang, W. X. The solution structure of rat Abeta-(1-28) and its interaction with zinc ion: Insights into the scarcity of amyloid deposition in aged rat brain. J. Biol. Inorg. Chem. 2004, 9, 627-635.
52. D'Ursi, A. M.; Armenante, M. R.; Guerrini, R.; Salvadori, S.; Sorrentino, G.; Picone, D. Solution structure of amyloid beta-peptide (25-35) in different media. J. Med. Chem. 2004, 47, 4231-4238.
53. Zirah, S.; Kozin, S. A.; Mazur, A. K.; Blond, A.; Cheminant, M.; Segalas-Milazzo, I.; Debey, P.; Rebuffat, S. Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J. Biol. Chem. 2006, 281, 2151-2161.
54. Istrate, A. N.; Tsvetkov, P. O.; Mantsyzov, A. B.; Kulikova, A. A.; Kozin, S. A.; Makarov, A. A.; Polshakov, V. I. NMR solution structure of rat Abeta(1-16): Toward understanding the mechanism of rats' resistance to Alzheimer's disease. Biophys. J. 2012, 102, 136-143.
55. Richard, T.; Papastamoulis, Y.; Pierre, W. T.; Monti, J. P. 3D NMR structure of a complex between the amyloid beta peptide (1-40) and the polyphenol epsilon-viniferin glucoside: Implications in Alzheimer's disease. Biochim. Biophys. Acta 2013, 1830, 5068-5074.
56. Colletier, J.; Laganowsky, A.; Landau, M.; Zhao, M.; Soriaga, A. B.; Goldschmidt, L.; Flot, D.; Cascio, D.; Sawaya, M. R.; Eisenberg, D. Molecular basis for Amyloid-β polymorphism. Proc. Natl. Acad. Sci. USA 2011, 108, 16938-16943.
57. Landau, M.; Sawaya, M. R.; Faull, K. F.; Laganowsky, A.; Jiang, L.; Sievers, S. A.; Liu, J.; Barrio, J. R.; Eisenberg, D. Towards a pharmacophore for amyloid. PLoS Biol. 2011, 9, e1001080.
58. Hoyer, W.; Gronwall, C.; Jonsson, A.; Stahl, S.; Hard, T. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. USA 2008, 105, 5099-5104.
59. Hynes, T. R.; Randal, M.; Kennedy, L. A.; Eigenbrot, C.; Kossiakoff, A. A. X-ray crystal structure of the protease inhibitor domain of Alzheimer's amyloid beta-protein precursor. Biochemistry 1990, 29, 10018-10022.
60. Perona, J. J.; Tsu, C. A.; McGrath, M. E.; Craik, C. S.; Fletterick, R. J. Relocating a negative charge in the binding pocket of trypsin. J. Mol. Biol. 1993, 230, 934-949.
61. Scheidig, A. J.; Hynes, T. R.; Pelletier, L. A.; Wells, J. A.; Kossiakoff, A. A. Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): Engineering of inhibitors with altered specificities. Protein Sci. 1997, 6, 1806-1824.
62. Zhang, Z.; Lee, C. H.; Mandiyan, V.; Borg, J. P.; Margolis, B.; Schlessinger, J.; Kuriyan, J. Sequence-specific recognition of the internalization motif of the Alzheimer's amyloid precursor protein by the X11 PTB domain. EMBO J. 1997, 16, 6141-6150.
63. Rossjohn, J.; Cappai, R.; Feil, S. C.; Henry, A.; McKinstry, W. J.; Galatis, D.; Hesse, L.; Multhaup, G.; Beyreuther, K.; Masters, C. L.; et al. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Mol. Biol. 1999, 6, 327-331.
64. Yun, M.; Keshvara, L.; Park, C. G.; Zhang, Y. M.; Dickerson, J. B.; Zheng, J.; Rock, C. O.; Curran, T.; Park, H. W. Crystal structures of the Dab homology domains of mouse disabled 1 and 2. J. Biol. Chem. 2003, 278, 36572-36581.
65. Barnham, K. J.; McKinstry, W. J.; Multhaup, G.; Galatis, D.; Morton, C. J.; Curtain, C. C.; Williamson, N. A.; White, A. R.; Hinds, M. G.; Norton, R. S.; et al. Structure of the Alzheimer's disease amyloid precursor protein copper binding Domain: A regulator of neuronal copper homeostasis. J. Biol. Chem. 2003, 278, 17401-17407.
66. Dulubova, I.; Ho, A.; Huryeva, I.; Sudhof, T. C.; Rizo, J. Three-dimensional structure of an independently folded extracellular domain of human amyloid-beta precursor protein. Biochemistry 2004, 43, 9583-9588.
67. Navaneetham, D.; Jin, L.; Pandey, P.; Strickler, J. E.; Babine, R. E.; Abdel-Meguid, S. S.; Walsh, P. N. Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the kunitz protease inhibitor domain of protease nexin 2. J. Biol. Chem. 2005, 280, 36165-36175.
68. Luhrs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Dobeli, H.; Schubert, D.; Riek, R. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA 2005, 102, 17342-17347.
69. Shen, Y.; Joachimiak, A.; Rosner, M. R.; Tang, W. J. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 2006, 443, 870-874.
70. Kong, G. K.; Adams, J. J.; Harris, H. H.; Boas, J. F.; Curtain, C. C.; Galatis, D.; Masters, C. L.; Barnham, K. J.; McKinstry, W. J.; Cappai, R.; et al. Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. J. Mol. Biol. 2007, 367, 148-161.
71. Kong, G. K.; Adams, J. J.; Cappai, R.; Parker, M. W. Structure of Alzheimer's disease amyloid precursor protein copper-binding domain at atomic resolution. Acta Crystallogr. Sect. F 2007, 63, 819-824.
72. Gardberg, A. S.; Dice, L. T.; Ou, S.; Rich, R. L.; Helmbrecht, E.; Ko, J.; Wetzel, R.; Myszka, D. G.; Patterson, P. H.; Dealwis, C. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2007, 104, 15659-15664.
73. Li, H.; Koshiba, S.; Hayashi, F.; Tochio, N.; Tomizawa, T.; Kasai, T.; Yabuki, T.; Motoda, Y.; Harada, T.; Watanabe, S.; et al. Structure of the C-terminal phosphotyrosine interaction domain of Fe65L1 complexed with the cytoplasmic tail of amyloid precursor protein reveals a novel peptide binding mode. J. Biol. Chem. 2008, 283, 27165-27178.
74. Miles, L. A.; Wun, K. S.; Crespi, G. A.; Fodero-Tavoletti, M. T.; Galatis, D.; Bagley, C. J.; Beyreuther, K.; Masters, C. L.; Cappai, R.; McKinstry, W. J.; et al. Amyloid-beta-antiamyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J. Mol. Biol. 2008, 377, 181-192.
75. Radzimanowski, J.; Simon, B.; Sattler, M.; Beyreuther, K.; Sinning, I.; Wild, K. Structure of the intracellular domain of the amyloid precursor protein in complex with Fe65-PTB2. Embo Rep. 2008, 9, 1134-1140.
76. Mirza, Z.; Vikram, G.; Singh, N.; Sinha, M.; Bhushan, A.; Sharma, S.; Srinivasan, A.; Kaur, P.; Singh, T. P. Phospholipase A2 prevents the aggregation of Amyloid beta peptides: Crystal structure of the complex of phospholipase A2 with octapeptide fragment of Amyloid beta peptide, Asp-Ala-Glu-Phe-Arg-His-Asp-Ser at 2 °A resolution. Available online: http://www. metalife. com/PDB/3JQ5 67427 (accessed on 6 June 2014).
77. Basi, G. S.; Feinberg, H.; Oshidari, F.; Anderson, J.; Barbour, R.; Baker, J.; Comery, T. A.; Diep, L.; Gill, D.; Johnson-Wood, K.; et al. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2010, 285, 3417-3427.
78. Guo, Q.; Manolopoulou, M.; Bian, Y.; Schilling, A. B.; Tang, W. J. Molecular basis for the recognition and cleavages of Igf-II, Tgf-Alpha, and amylin by human insulin degrading enzyme. J. Mol. Biol. 2010, 395, 430-443.
79. Dahms, S. O.; Hoefgen, S.; Roeser, D.; Schlott, B.; Guhrs, K. H.; Than, M. E. Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 2010, 107, 5381-5386.
80. Burgos, P. V.; Mardones, G. A.; Rojas, A. L.; daSilva, L. L.; Prabhu, Y.; Hurley, J. H.; Bonifacino, J. S. Sorting of the Alzheimer's disease amyloid precursor protein mediated by the AP-4 complex. Dev. Cell 2010, 18, 425-436.
81. Pandey, N.; Mirza, Z.; Vikram, G.; Singh, N.; Bhushan, A.; Kaur, P.; Srinivasan, A.; Sharma, S.; Singh, T. P. Crystal structure of the complex formed between Phospholipase A2 with beta-amyloid fragment, Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met at 1. 8 °A resolution. Available online: http://www. metalife. com/PDB/3JTI 67538 (accessed on 10 June 2014).
82. Salameh, M. A.; Soares, A. S.; Navaneetham, D.; Sinha, D.; Walsh, P. N.; Radisky, E. S. Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin. J. Biol. Chem. 2010, 285, 36884-36896.
83. Streltsov, V. A.; Varghese, J. N.; Masters, C. L.; Nuttall, S. D. Crystal structure of the amyloid-beta p3 fragment provides a model for oligomer formation in Alzheimer's disease. J. Neurosci. 2011, 31, 1419-1426.
84. Das, S.; Raychaudhuri, M.; Sen, U.; Mukhopadhyay, D. Functional implications of the conformational switch in AICD peptide upon binding to Grb2-SH2 domain. J. Mol. Biol. 2011, 414, 217-230.
85. Lee, S.; Xue, Y.; Hu, J.; Wang, Y.; Liu, X.; Demeler, B.; Ha, Y. The E2 domains of APP and APLP1 share a conserved mode of dimerization. Biochemistry 2011, 50, 5453-5464.
86. Wang, Y.; Ha, Y. The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol. Cell 2004, 15, 343-353.
87. Colletier, J.; Laganowsky, A.; Landau, M.; Zhao, M.; Soriaga, A. B.; Goldschmidt, L.; Flot, D.; Cascio, D.; Sawaya, M. R.; Eisenberg, D. Molecular basis for amyloid-beta polymorphism. Proc. Natl. Acad. Sci. USA 2011, doi: 10. 1073/pnas. 1112600108.
88. Hashimoto, H.; Takeuchi, T.; Komatsu, K.; Miyazaki, K.; Sato, M.; Higashi, S. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of beta-amyloid precursor protein-derived inhibitor. J. Biol. Chem. 2011, 286, 33236-33243.
89. Petkova, A.; Yau, W.; Tycko, R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry 2006, 45, 498-512.
90. Paravastu, A.; Leapman, R.; Yau, W.; Tycko, R. Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc. Natl. Acad. Sci. USA 2008, 105, 18349-18354.
91. Qiang, W.; Yau, W. M.; Luo, Y.; Mattson, M. P.; Tycko, R. Antiparallel beta-sheet architecture in Iowa-mutant beta-amyloid fibrils. Proc. Natl. Acad. Sci. USA 2012, 109, 4443-4448.
92. Nadezhdin, K. D.; Bocharova, O. V.; Bocharov, E. V.; Arseniev, A. S. Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment. Febs Lett. 2012, 586, 1687-1692.
93. Barrett, P. J.; Song, Y.; Horn, W. D. V.; Hustedt, E. J.; Schafer, J. M.; Hadziselimovic, A.; Beel, A. J.; Sanders, C. R. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012, 336, 1168-1171.
94. Nadezhdin, K. D.; Bocharova, O. V.; Bocharov, E. V.; Arseniev, A. S. Structural and dynamic study of the transmembrane domain of the amyloid precursor protein. Acta Nat. 2011, 3, 69-76.
95. Porte, S. L. L.; Bollini, S. S.; Lanz, T. A.; Abdiche, Y. N.; Rusnak, A. S.; Ho, W. H.; Kobayashi, D.; Harrabi, O.; Pappas, D.; Mina, E. W.; et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J. Mol. Biol. 2012, 421, 525-536.
96. Dahms, S. O.; Konnig, I.; Roeser, D.; Guhrs, K. H.; Mayer, M. C.; Kaden, D.; Multhaup, G.; Than, M. E. Metal binding dictates conformation and function of the amyloid precursor protein (APP) E2 domain. J. Mol. Biol. 2012, 416, 438-452.
97. Xie, X.; Yan, X.; Wang, Z.; Zhou, H.; Diao, W.; Zhou, W.; Long, J.; Shen, Y. Open-closed motion of Mint2 regulates APP metabolism. J. Mol. Cell Biol. 2013, 5, 48-56.
98. Miles, L. A.; Crespi, G. A.; Doughty, L.; Parker, M. W. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci. Rep. 2013, doi: 10. 1038/srep01302.
99. Lu, J. X.; Qiang, W.; Yau, W. M.; Schwieters, C. D.; Meredith, S. C.; Tycko, R. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 2013, 154, 1257-1268.
100. Chen, W.; Lopez, M.; Gamache, E.; Li, Y.; Wang, C. Familial Alzheimer's mutation V44M promotes helical unwinding at the β-cleavage site for Abeta42 production. Nat. Commun. 2014, 5, 3037.
101. Nguyen, P. H.; Derreumaux, P. Conformational ensemble and polymorphism of the all-atom Alzheimer's Abeta(37-42) amyloid peptide oligomers. J. Phys. Chem. B 2013, 117, 5831-5840.
102. Jang, S.; Shin, S. Amyloid β-peptide oligomerization in silico: Dimer and trimer. J. Phys. Chem. B 2006, 110, 1955-1958.
103. Nguyen, P. H.; Li, M. S.; Derreumaux, P. Effects of all-atom force fields on amyloid oligomerization: Replica exchange molecular dynamics simulations of the Abeta(16-22) dimer and trimer. Phys. Chem. Chem. Phys. 2011, 13, 9778-9788.
104. Chebaro, Y.; Mousseau, N.; Derreumaux, P. Structures and thermodynamics of Alzheimer's amyloid-beta Abeta(16-35) monomer and dimer by replica exchange molecular dynamics simulations: Implication for full-length Abeta fibrillation. J. Phys. Chem. B 2009, 113, 7668-7675.
105. Urbanc, B.; Cruz, L.; Ding, F.; Sammond, D.; Khare, S.; Buldyrev, S. V.; Stanley, H. E.; Dokholyan, N. V. Molecular dynamics simulation of amyloid β dimer formation. Biophys. J. 2004, 87, 2310-2321.
106. Xu, Y.; Shen, J.; Luo, X.; Zhu, W.; Chen, K.; Ma, J.; Jiang, H. Conformational transition of amyloid β-peptide. Proc. Natl. Acad. Sci. USA 2005, 102, 5403-5407.
107. Lemkul, J. A.; Bevan, D. R. A comparative molecular dynamics analysis of the amyloid β-peptide in a lipid bilayer. Arch. Biochem. Biophys. 2008, 470, 54-63.
108. Lu, Y.; Derreumaux, P.; Guo, Z.; Mousseau, N.; Wei, G. Thermodynamics and dynamics of amyloid peptide oligomerization are sequence dependent. Proteins 2009, 75, 954-963.
109. Bitan, G.; Kirkitadze, M. D.; Lomakin, A.; Vollers, S. S.; Benedek, G. B.; Teplow, D. B. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA 2003, 100, 330-335.
110. Cote, S.; Laghaei, R.; Derreumaux, P.; Mousseau, N. Distinct dimerization for various alloforms of the amyloid-beta protein: Abeta(1-40), Abeta(1-42), and Abeta(1-40)(D23N). J. Phys. Chem. B 2012, 116, 4043-4055.
111. Leoni, V.; Solomon, A.; Kivipelto, M. Links between ApoE brain cholesterol metabolism, tau and amyloid β-peptide in patients with cognitive impairment. Biochem. Soc. Trans. 2010, 38, 1021-1025.
112. Zhao, L. N.; Chiu, S. W.; Benoit, J.; Chew, L. Y.; Mu, Y. Amyloid β peptide aggregation in a mixed membrane bilayer: A molecule dynamic study. J. Phys. Chem. B 2011, 115, 12247-12256.
113. Friedrich, R. P.; Tepper, K.; Rönicke, R.; Soom, M.; Westermann, M.; Reymann, K.; Kaether, C.; Fändrich, M. Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity. Proc. Natl. Acad. Sci. USA 2010, 107, 1942-1947.
114. Zhao, L. N.; Chiu, S. W.; Benoit, J.; Chew, L. Y.; Mu, Y. The effect of curcumin on the stability of Aβ dimers. J. Phys. Chem. B 2012, 116, 7428-7435.
115. Chebaro, Y.; Jiang, P.; Zang, T.; Mu, Y.; Nguyen, P. H.; Mousseau, N.; Derreumaux, P. Structures of Abeta17-42 trimers in isolation and with five small-molecule drugs using a hierarchical computational procedure. J. Phys. Chem. B 2012, 116, 8412-8422.
116. Zhao, L. N.; Mu, Y.; Chew, L. Y. Heme prevents amyloid beta peptides aggregation through hydrophobic interaction based on molecular dynamics simulation. Phys. Chem. Chem. Phys. 2013, 15, 14098-14106.
117. Jiang, P.; Li, W. F.; Shea, J. E.; Mu, Y. Resveratrol inhibits the formation of multiple-layered β-sheet oligomers of the human islet amyloid polypeptide segment 22-27. Biophys. J. 2011, 100, 1550-1558.
118. Colombo, R.; Carotti, A.; Catto, M.; Racchi, M.; Lanni, C.; Verga, L.; Caccialanza, G.; Lorenzi, E. D. CE can identify small molecules that selectively target soluble oligomers of amyloid β protein and display antifibrillogenic activity. Electrophoresis 2009, 30, 1418-1429.
119. Cohen, A. D.; Ikonomovic, M. D.; Abrahamson, E. E.; Paljug, W. R.; DeKosky, S. T.; Lefterov, I. M.; Koldamova, R. P.; Shao, L.; Debnath, M. L.; Mason, N. S.; et al. Anti-amyloid effects of small molecule Aβ-binding agents in PS1/APP mice. Lett. Drug. Des. Discov. 2009, 6, 437.
120. Zhang, T.; Xu, W.; Mu, Y.; Derreumaux, P. Atomic and dynamic insights into the beneficial effect of the 1, 4-naphthoquinon-2-yl-L-tryptophan inhibitor on Alzheimer's Abeta1-42 dimer in terms of aggregation and toxicity. ACS Chem. Neurosci. 2014, 5, 148-159.
121. Zhang, T.; Zhang, J.; Derreumaux, P.; Mu, Y. Molecular mechanism of the inhibition of EGCG on the Alzheimer Abeta(1-42) dimer. J. Phys. Chem. B 2013, 117, 3993-4002.
122. Zhao, L. N.; Zhang, T.; Zhang, C.; Wang, C.; Morozova-Roche, L. A.; Chew, L. Y.; Mu, Y. S100A9 induces aggregation-prone conformation in Abeta peptides: A combined experimental and simulation study. RSC Adv. 2013, 3, 24081-24089.
123. Nguyen, P. H.; Tarus, B.; Derreumaux, P. Familial Alzheimer A2V mutation reduces the intrinsic disorder and completely changes the free energy landscape of the Abeta1-28 monomer. J. Phys. Chem. B 2014, 118, 501-510.
124. Viet, M. H.; Nguyen, P. H.; Ngo, S. T.; Li, M. S.; Derreumaux, P. Effect of the Tottori familial disease mutation (D7N) on the monomers and dimers of Abeta40 and Abeta42. ACS Chem. Neurosci. 2013, 4, 1446-1457.
125. Nguyen, P.; Derreumaux, P. Understanding amyloid fibril nucleation and abeta oligomer/drug interactions from computer simulations. Acc. Chem. Res. 2014, 47, 603-611.
126. Kodalia, R.; Williams, A. D.; Chemuru, S.; Wetzel, R. Aβ(1-40) forms five distinct amyloid structures whose β-sheet contents and fibril stabilities are correlated. J. Mol. Biol. 2010, 401, 503-517.
127. Tycko, R. β-Amyloid fibril structures, in vitro and in vivo. In Proteopathic Seeds and Neurodegenerative Diseases, Research and Perspectives in Alzheimer's Disease; Springer: Berlin, Germany, 2013; Volume 155, pp. 19-36.
128. Hard, T. Amyloid fibrils: Formation, polymorphism, and inhibition. J. Phys. Chem. Lett. 2014, 5, 607-614.
129. Nguyen, P. H.; Li, M. S.; Stock, G.; Straub, J. E.; Thirumalai, D. Monomer adds to preformed structured oligomers of Aβ-peptides by a two-stage dock-lock mechanism. Proc. Natl. Acad. Sci. USA 2007, 104, 111-116.
130. Welander, H.; Franberg, J.; Graff, C.; Sundstrm, E.; Winblad, B.; Tjernberg, L. O. Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains. J. Neurochem. 2009, 110, 697-706.
131. Iwatsubo, T.; Odaka, A.; Suzuki, N.; Mizusawa, H.; Nukina, N.; Ihara, Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 1994, 13, 45-53.
132. Portelius, E.; Zetterberg, H.; Dean, R. A.; Marcil, A.; Bourgeois, P.; Nutu, M.; Andreasson, U.; Siemers, E.; Mawuenyega, K. G.; Sigurdson, W. C.; et al. Amyloid-β(1-15=16) as a marker for-secretase inhibition in Alzheimer's disease. J. Alzheimers Dis. 2012, 31, 335-341.
133. Wiltfang, J.; Esselmann, H.; Bibl, M.; Smirnov, A.; Otto, M.; Paul, S.; Schmidt, B.; Klafki, H. W.; Maler, M.; Dyrks, T.; et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37=38=39 in addition to 1-40=42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 2002, 81, 481-496.
134. Portelius, E.; Tran, A. J.; Andreasson, U.; Persson, R.; Brinkmalm, G.; Zetterberg, H.; Blennow, K.; Westman-Brinkmalm, A. Characterization of amyloid β peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 2007, 6, 4433-4439.
135. Bouter, Y.; Dietrich, K.; Wittnam, J. L.; Rezaei-Ghaleh, N.; Pillot, T.; Papot-Couturier, S.; Lefebvre, T.; Sprenger, F.; Wirths, O.; Zweckstetter, M.; et al. N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol. 2013, 126, 189-206.
136. Jawhar, S.; Wirths, O.; Bayer, T. A. Pyroglutamate amyloid-β (Aβ): A hatchet man in Alzheimer disease. J. Biol. Chem. 2011, 286, 38825-38832.
137. Harigaya, Y.; Saido, T. C.; Eckman, C. B.; Prada, C. M.; Shoji, M.; Younkin, S. G. Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem. Biophys. Res. Commun. 2000, 276, 422-427.
138. Perez-Garmendia, R.; Gevorkian, G. Pyroglutamate-modified amyloid beta peptides: Emerging targets for Alzheimer's disease immunotherapy. Curr. Neuropharmacol. 2013, 11, 491-498.
139. Bayer, T. A.; Wirths, O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol. 2014, 127, 787-801.
140. Haass, C.; Schlossmacher, M. G.; Hung, A. Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B. L.; Lieberburg, I.; Koo, E. H.; Schenk, D.; Teplow, D. B.; et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359, 322-325.
141. Russo, C.; Saido, T. C.; DeBusk, L. M.; Tabaton, M.; Gambetti, P.; Teller, J. K. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett. 1997, 409, 411-416.
142. Sevalle, J.; Amoyel, A.; Robert, P.; Fournie-Zaluski, M. C.; Roques, B.; Checler, F. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J. Neurochem. 2009, 109, 248-256.
143. Sun, N.; Hartmann, R.; Lecher, J.; Stoldt, M.; Funke, S. A.; Gremer, L.; Ludwig, H.; Demuth, H.; Kleinschmidt, M.; Willbold, D. Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-beta using NMR spectroscopy. J. Pept. Sci. 2012, 18, 691-695.
144. Wirths, O.; Erck, C.; Martens, H.; Harmeier, A.; Geumann, C.; Jawhar, S.; Kumar, S.; Multhaup, G.; Walter, J.; Ingelsson, M.; et al. Identification of low molecular weight pyroglutamate Aβ oligomers in Alzheimer disease. J. Biol. Chem. 2010, 285, 41517-41524.
145. Wirths, O.; Breyhan, H.; Cynis, H.; Schilling, S.; Demuth, H. U.; Bayer, T. A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118, 487-696.
146. LaFerla, F. M. Pathways linking Aβ and tau pathologies. Biochem. Soc. Trans. 2010, 38, 993-995.
147. Gouras, G. K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J. P.; Haroutunian, V.; Buxbaum, J. D.; Xu, H.; et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156, 15-20.
148. Rissman, R.; Poon, W. W.; Blurton, M.; Oddo, S.; Torp, R.; Vitek, M.; LaFerla, F.; Rohn, T. T. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Investig. 2004, 114, 121-130.
149. Blurton-Jones, M.; LaFerla, F. M. Pathways by which Abeta facilitates tau pathology. Curr. Alzheimer Res. 2006, 3, 437-448.
150. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch. Pharm. Res. 2013, 36, 357-399.